Head to Head Survey: Nyxoah (NASDAQ:NYXH) vs. Nephros (NASDAQ:NEPH)

Nephros (NASDAQ:NEPH) and Nyxoah (NASDAQ:NYXH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability and earnings.

Earnings & Valuation

This table compares Nephros and Nyxoah”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79 million	2.04	$1.19 million	$0.16	22.06
Nyxoah	$11.33 million	4.65	-$101.92 million	($2.52)	-0.54

Nephros has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nephros and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nephros	8.38%	10.60%	8.05%
Nyxoah	-443.16%	-178.90%	-81.83%

Analyst Recommendations

This is a summary of recent recommendations for Nephros and Nyxoah, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0	3	1	0	2.25
Nyxoah	1	1	2	0	2.25

Nephros currently has a consensus price target of $4.00, indicating a potential upside of 13.31%. Nyxoah has a consensus price target of $4.26, indicating a potential upside of 213.38%. Given Nyxoah’s higher possible upside, analysts clearly believe Nyxoah is more favorable than Nephros.

Risk and Volatility

Nephros has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.

Institutional and Insider Ownership

41.1% of Nephros shares are owned by institutional investors. 6.7% of Nephros shares are owned by insiders. Comparatively, 17.1% of Nyxoah shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Nephros beats Nyxoah on 8 of the 13 factors compared between the two stocks.

About Nephros

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.